Spotlight On TissueGene’s Upcoming Korea IPO

Regenerative drug company TissueGene’s proposed IPO in South Korea is drawing keen interest, coming close on the heels of the recent approval of its novel osteoarthritis drug in the country. Success of the IPO will be crucial for the company to proceed with a Phase III US study of the drug.

Money Wave

TissueGene Inc. is gearing to launch an initial public offering in South Korea to finance a Phase III US clinical trial of Invossa, its first-in-class cell and gene therapy drug. Invossa was approved by South Korean authorities in July making it the country's first gene therapy and the world’s first allogeneic cell mediated gene therapy for degenerative osteoarthritis.

The US-based TissueGene, which is part of South Korea’s Kolon Group, aims to raise KRW120bn ($105.7m) to KRW202.5bn from the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip